T1	Participants 826 940	4-arm clinical trial in patients with myeloid leukemia undergoing allogeneic stem cell transplantation (allo-SCT).
T2	Participants 1323 1360	Fifty-one patients have been enrolled
T3	Participants 1407 1485	here were 32 males and 19 females, with a median age of 45 years (range: 6-59)
T4	Participants 1487 1529	Nine patients had chronic myeloid leukemia
T5	Participants 1629 1655	Forty-two patients had AML
T6	Participants 1657 1906	14 were induction failures, 8 in first chemotherapy-refractory relapse, 7 in untreated relapse, 3 in second or subsequent relapse, 4 were in second complete remission (CR), and 3 in second CR without platelet recovery (CRp), 2 were in high-risk CR1.
T7	Participants 2140 2162	All patients engrafted
T8	Participants 2164 2248	Forty-one patients had active leukemia at the time of transplant, and 35 achieved CR
T9	Participants 2256 2379	Twenty of the 42 AML patients and 5 of 9 CML patients are alive with a projected median overall survival (OS) of 23 months.
